L, I., & F, d. Z. (2005). Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: The key role of metformin at the start and after more than one year of therapy.
Citación estilo ChicagoL, Ibáñez, y de Zegher F. Flutamide-metformin Plus Ethinylestradiol-drospirenone for Lipolysis and Antiatherogenesis in Young Women With Ovarian Hyperandrogenism: The Key Role of Metformin At the Start and After More Than One Year of Therapy. 2005.
Cita MLAL, Ibáñez, y de Zegher F. Flutamide-metformin Plus Ethinylestradiol-drospirenone for Lipolysis and Antiatherogenesis in Young Women With Ovarian Hyperandrogenism: The Key Role of Metformin At the Start and After More Than One Year of Therapy. 2005.